Atypical Antipsychotic Drugs for Schizophrenia: Access, Reimbursement and the Struggle for Parity

Atypical Antipsychotic Drugs for Schizophrenia: Access, Reimbursement and the Struggle for Parity

DSpace/Manakin Repository

Atypical Antipsychotic Drugs for Schizophrenia: Access, Reimbursement and the Struggle for Parity

dc.contributor.advisor	Hutt, Peter Barton	en_US
dc.contributor.author	Kim, Sandra	en_US
dc.date.accessioned	2012-07-06T21:38:45Z
dc.date.issued	2002	en_US
dc.identifier.citation	Atypical Antipsychotic Drugs for Schizophrenia: Access, Reimbursement and the Struggle for Parity (2002 Third Year Paper)	en
dc.identifier.uri	http://nrs.harvard.edu/urn-3:HUL.InstRepos:8965593
dc.description.abstract	This paper discusses the impact of schizophrenia on American society and advocates for health care reform to address the lack of access by the mentally ill to a class of innovative drugs, called â€&oelig;atypical anti-psychotics.â€ Atypical anti-psychotic drugs, including clozapine, risperidone and olanzapine are crucial for the treatment of both the positive and negative symptoms of schizophrenia and should be made available as first-line treatments for schizophrenics. Current health care policies and reforms provide facially attractive benefits, but lack significant practical benefits, resulting in obstacles to access to these life-changing medications. Health care reforms providing adequate reimbursement for these medications, and thereby opening access to them on a first-line basis, would in fact relieve financial pressures on our health care system instead of creating further strain on scarce resources by reducing funds spent on hospitalization and other medical resources.	en
dc.language.iso	en_US	en
dash.license	LAA	en_US
dc.subject	Food and Drug Law	en
dc.subject	drugs	en
dc.subject	schizophrenia	en
dc.subject	anti-psychotic	en
dc.title	Atypical Antipsychotic Drugs for Schizophrenia: Access, Reimbursement and the Struggle for Parity	en
dc.type	Paper (for course/seminar/workshop)	en_US
dc.date.available	2012-07-06T21:38:45Z